University of Pennsylvania’s Abramson Cancer Center

Penn’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Its preeminent position is reflected in their continuous designation as a Comprehensive Cancer Center by the National Cancer Institute since 1973, one of 41 such Centers in the United States. The clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists, and patent care coordinators, currently sees over 90,000 outpatient visits, over 11,800 inpatient discharges, and provides over 37,000 chemotherapy treatments, and more than 66,000 radiation treatments. In addition, the Abramson Cancer Center is home to the 400+ basic, translational, and clinical scientists who work relentlessly to determine the pathogenesis of cancer.

MD Anderson Cancer Center at Cooper

Through our collaboration with the Wistar Institute, doctors from the MD Anderson Cancer Center at Cooper are participating in ITUS’s cancer biomarker study. The MD Anderson Cooper facility offers expanded programs and services in an environment that fosters a team approach to medicine. Cancer specialists from various medical disciplines conduct concurrent, complementary clinical sessions with patients, fostering professional interaction and collaboration. Patients benefit from easy access to advanced treatment technologies and a full range of supportive care services.

The Wistar Institute Cancer Center

Founded in 1892 as the nation’s first independent biomedical research institute and located on the campus of the University of Pennsylvania, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI’s select network of national cancer research centers, holding an ‘Exceptional’ rating — the highest possible ranking awarded.

Penn Medicine Virtua Cancer Program

The Penn Medicine Virtua Cancer Program is accredited by both the American College of Surgeons (ACos) and by the National Accreditation Program for Breast Centers. As one of 74 nationally accredited cancer programs to be awarded the Commission on Cancer by the ACoS, Virtua raises the bar on quality cancer care and increases awareness about quality choices among patients with cancer, as well as their loved ones. Virtua provides a full range of clinical oncology social work services to meet the psychological needs of cancer patients and their families.

Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System

Through our collaboration with the Wistar Institute, doctors from the Helen F. Graham Cancer Center & Research Institute are participating in ITUS’s cancer biomarker study. The Helen F. Graham Cancer Center & Research Institute is part of Christiana Care Health System, one of the country’s largest health care systems, ranking as the 22nd leading hospital in the nation and 12th on the East Coast in terms of patient admissions. The Helen F. Graham Cancer Center & Research Institute has more cancer patients enrolled in clinical trials than virtually any other program in the country, with physicians and researchers committed to developing and providing innovative technologies and the highest standards of patient care.

Delaware Valley Urology

Delaware Valley Urology (DVU) is the largest urology practice in the South Jersey and greater Philadelphia Region, focusing on the advanced diagnosis and treatment of urological conditions including Prostate Cancer, Bladder Cancer, and Kidney cancer. DVU is accredited by the American College of Radiology, the premier credentialing body for radiation oncology. Their practice consists of over 30 physicians who perform more than 1,200 prostate biopsies each year.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith


ITUS Presentation to Special Meeting of Stockholders


ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study


Cancer Fact: Lung cancer accounts for 13% of worldwide cancer incidences.